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a  b  s  t  r  a  c  t
Regulatory  T cells  (Treg)  inﬂuence  the development  of  autoimmunity  and  their use is increasingly  pro-
posed  for  clinical  applications.  The  well-characterized  suppressive  potential  of Treg frequently  leads
to the  assumption  that  Treg  presence  in  prevailing  numbers  is indicative  of immunosuppression.  We
hypothesized  that  this  assumption  may  be  false.  We examined  models  of  three  different  diseases  caused
by  organ-speciﬁc  autoimmune  responses:  primary  biliary  cirrhosis,  atherosclerosis  and  rheumatoid
arthritis  (RA).  We examined  indicators  of  relative  abundance  of Treg  compared  to  pro-inﬂammatory
T  cells,  during  peak  inﬂammation.  In  all  cases,  the  results  were  compatible  with  a relative  enrichment  of
Treg at  the  site  of inﬂammation  or its  most  proximal  draining  lymph  node.  Conversely,  in healthy  mice
or  mice  successfully  protected  from  disease  via  a Treg-mediated  mechanism,  the  data  did  not  suggest
that  any  Treg  accumulation  was occurring.  This  counter-intuitive  ﬁnding  may  appear  to  be  at  odds  with
the immunosuppressive  nature  of  Treg.  Yet  extensive  previous  studies  in  RA  show  that  an  accumulationutoimmunity of  Treg  occurs  at peak inﬂammation,  albeit  without  resulting  in  suppression,  as  the Treg  suppressive
function  is overcome  by the cytokine-rich  environment.  We  suggest  that  this  is a ubiquitous  feature  of
autoimmune  inﬂammation.  Treg  abundance  in  patient  samples  is  increasingly  used  as  an  indicator  of  a
state of  immunosuppression.  We  conclude  that this  strategy  should  be revisited  as it may  potentially  be
a source  of  misinterpretation.
©  2015  The  Authors.  Published  by Elsevier  GmbH.  This  is an  open  access  article  under  the  CC  BYntroduction
Foxp3+ Regulatory T cells (Treg) affect disease development in
utoimmunity and unwanted inﬂammation (Wing and Sakaguchi,
010). A large number of studies (Allan et al., 2008), mostly on
nimal models, have associated defects in Treg cells with the
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development of autoimmune symptoms (Zhang et al., 2009), whilst
experimental administration of Treg protects from autoimmunity
(Munoz-Suano et al., 2012). Their use is increasingly proposed for
clinical applications (Wing and Sakaguchi, 2010). Whilst aspects of
their dynamic behavior during physiological conditions are under-
stood (Liston and Gray, 2014), little is known about how Treg
behave during an ongoing autoimmune inﬂammatory response
(Torgerson, 2006; Germain, 2012). Scientists often conceptualize a
balance of anti-inﬂammatory Treg versus pro-inﬂammatory effec-
tor T (Teff) cells, with the most numerous population determining
the outcome of the response: tolerance versus autoimmunity. This
is increasingly used in clinical studies, examining Treg abundance
in patients’ peripheral blood (Koﬂer et al., 2011). The balance
le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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etaphor is likely to be valid during the start of a response, when
reg failure in suppressing Teff may  be the initiating event of
utoimmunity. We  hypothesized that this may  not be so during
he peak of autoimmunity. In other words, once an autoimmune
nﬂammatory response has been established, Treg may  be unable
o control it, even if they accumulate in higher numbers in their
ttempt to do so. Intriguingly, extensive studies in rheumatoid
rthritis (RA) have shown that Treg are enriched in the inﬂamed
ynovium. Mechanistic insight derived from these studies demon-
trates that Treg do not succeed in suppressing the response as they
re impeded or overwhelmed by local pro-inﬂammatory cytokines
Benito-Miguel et al., 2009; Nguyen et al., 2007; Nie et al., 2013).
imilar data have also been produced and published for many other
utoimmune diseases, even though in most cases the counter-
ntuitive Treg accumulation was evidenced but not highlighted
Maganto-Garcia et al., 2011; Patel et al., 2010). In some of the older
tudies, especially from human patients, the difﬁculty in obtaining
atient samples other than peripheral blood, the unreliable identi-
cation of Treg cells prior to the availability of Foxp3 as a marker
nd the more promiscuous expression of Foxp3 as a Treg marker
n the human have often inhibited the drawing of ﬁrm conclu-
ions (Torgerson, 2006). Yet, especially in the mouse, where Foxp3
xpression has a better correlation – albeit not perfect (Miyao et al.,
012; Sharma et al., 2010) – with suppressive function (Rubtsov
t al., 2010; Hori, 2011) the data is indeed convincing that such an
nrichment takes place (Nguyen et al., 2007). To assess whether this
ounter-intuitive observation applies to a wider range of diseases,
e retrospectively examined unpublished data generated in our
aboratories using three different model autoimmune pathologies.
ur results, together with the extensive data published in the con-
ext of previous studies on different autoimmune diseases, suggest
hat it may  be unwise to use Treg enrichment in an autoimmune
nﬂammation context as an indicator of successful immunosup-
ression.
aterials and methods
isease models
All animal handling was performed by expert technicians,
ccording to the national legislation and local committee regula-
ions of the authors’ institutes.
BC induction
We  used the PBC mouse model as described in (Wakabayashi
t al., 2008). Female C57BL/6 mice at 6 weeks of age (Charles River)
ere immunized intra-peritoneally with a mixture of 138-BSA
2-octynoic acid (OA)-BSA; 100 g/50 L) in Complete Freund’s
djuvant (CFA; Sigma–Aldrich) containing 10 mg/mL of Mycobac-
erium tuberculosis strain H37Ra and subsequently boosted every
 weeks, for a total of 8 weeks, with 2OA-BSA and Incom-
lete Freund’s Adjuvant (IFA; Sigma–Aldrich). Pertussis toxin was
dministered at day 0 and 2 (100 ng/mouse). 2OA (Sigma–Aldrich)
as conjugated to BSA as described previously (Wakabayashi
t al., 2008). Serum titers of antiPDC-E2 autoantibodies were mea-
ured by enzyme-linked immunosorbent assay using standardized
ecombinant auto antigens.
low cytometry
Single cell suspensions were prepared from harvested tissue by
assing through 70 m cell strainers (BD) and lysing red blood cells
sing Lysing Buffer (BD). Livers had been additionally previously
egmented by scalpel and incubated for 1.5 h in RPMI 1640 medium
Lonza) containing 0.05% collagenase type IV (Sigma–Aldrich) aty 220 (2015) 1025–1029
37 ◦C. Treg and Teff populations in harvested lymphoid tissue were
assessed by ﬂow cytometry on a FACSCanto II (BD Biosciences)
using rat anti-mouse CD4-PerCP-Cy5.5 (BD, clone RM 4-5) and
rat anti-mouse FoxP3-AlexaFluor488 (eBioscience, clone FJK-16s)
antibodies.
Atherosclerosis models
Low Density Lipoprotein (LDL) receptor deﬁcient mice or
apolipoprotein E (ApoE) deﬁcient mice or C57BL/6 controls were
fed ad libitum with an atherogenic western type diet (21% fat, 0.15%
cholesterol and 19.5% casein, Harlan) starting at 8 weeks of age, for
16 weeks. Mice were sacriﬁced for analysis after anesthetization
with an overdose of Avertin 2.5% (Aldrich Chemical Co), followed
by cervical dislocation. Aorta isolation, mRNA extraction and cDNA
preparation were performed as described previously (Norata et al.,
2012).
CIA induction
Induction was  performed as described previously (Munoz-
Suano et al., 2012). Brieﬂy, female C57BL/6 mice were immunized
intradermally with 100 g chicken collagen II (Sigma–Aldrich) in
CFA on day 0 and 21. Mice were monitored for signs of arthri-
tis and for anti-collagen antibodies. The humane end-point was
set at a clinical score of ≥8 out of 12. Mice were considered
arthritic when having a score ≥3. Joints were obtained during week
6 post-CIA induction, when the incidence reaches a plateau, for
mRNA extraction and qPCR analysis. Treg-mediated, pregnancy-
associated protection from CIA symptoms, as described previously
(Munoz-Suano et al., 2012), was achieved by mating the female
mice with allogeneic BALB/c males on day 31 post-CIA induction.
RNA was  harvested using RNeasy kit (Qiagen). cDNA was  synthe-
sized using Superscript II RT (Invitrogen). mRNA expression levels
were measured using Taqman Gene Expression assays (Applied
Biosystems) for CD3e and custom-made primers for Foxp3 and
HPRT, as described previously (Kallikourdis and Betz, 2007).
Statistical analysis
Statistical analysis was performed with GraphPad Prism soft-
ware, using unpaired t-test for Gaussian or Mann–Whitney test for
non-Gaussian distributions, after normality testing.
Results
Atherosclerosis is characterized by T cell responses to vascu-
lar self-antigens. Mice deﬁcient in the receptor for low-density
lipoprotein (LDL) or in apolipoprotein E develop hypercholes-
terolemia and subsequent atherosclerosis when fed an atherogenic
diet (Ammirati et al., 2012). Using real-time qPCR, we examined the
ratio of Foxp3 to CD4 mRNA, as an indicator of the relative abun-
dance of Treg in the tissue. The ratio was signiﬁcantly increased in
the ascendant aortic arch of mice with atherosclerosis compared to
controls (Fig. 1A; P < 0.05, unpaired t test).
Primary biliary cirrhosis (PBC) is an autoimmune disease target-
ing the liver small bile ducts. We  used the murine model of PBC, at
8 weeks post-induction, when the inﬂammation reaches a plateau
(Wakabayashi et al., 2008). The percentage of Foxp3+ cells within
the CD4+ T cell population, examined by ﬂow cytometry, was not
signiﬁcantly different in para-aortic lymph nodes and spleens of
mice with induced PBC compared to healthy mice (Supplementary
Fig. 1A and B). Yet, in the liver-draining hepatic lymph nodes of
mice with PBC, CD4+ Foxp3+ cells were 23.8 ± 1.2% of CD4+ T cells,
compared to only 12.2 ± 0.8% in healthy controls (Fig. 1B; P = 0.0014,
S. Garetto et al. / Immunobiology 220 (2015) 1025–1029 1027
A B C
Fig. 1. Regulatory T cell enrichment during peak inﬂammation in mouse models of organ-speciﬁc autoimmunity. (A) Atherosclerosis: The ratio of Treg to Teff, as indicated
by  the relative levels of FoxP3 to CD4 mRNA measured by real-time qPCR analysis, in aortic samples from C57BL/6 control mice or atherosclerotic mice; P = 0.0289, unpaired
t  test. Values shown are normalized to the mean of control animals. Each dot represents one animal: n = 5 control mice; n = 4 ApoE−/− and n = 4 LDLR−/− mice, pooled for this
analysis (B) Primary biliary cirrhosis: Flow cytometric analysis of FoxP3 positive cells among CD4 positive cells in mice with induced PBC or control C57BL/6 mice. Hepatic
lymph  nodes; P = 0.0014, Mann–Whitney test. Each dot represents one animal: n = 7 and 8 animals, pooled from two independent PBC induction preparations. (C) Collagen
Induced Arthritis. The ratio of Treg to total T cells, as indicated by the relative levels of FoxP3 to CD3 mRNA measured by real-time qPCR analysis, in the joints of arthritic
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rotected from arthritis. Each dot represents one animal: n = 7 and 5 animals, poole
on-parametric t test). The liver itself in animals with PBC showed
 similar signiﬁcant Treg enrichment (Supplementary Fig. 1C).
Supplementary Fig. S1 related to this article can be found, in the
nline version, at http://dx.doi.org/10.1016/j.imbio.2015.02.006.
Pregnancy, via the action of Treg, alleviates the symptoms of
rthritis, as we have recently shown in the collagen-induced arthri-
is (CIA) model of RA (Munoz-Suano et al., 2012). We  examined,
ia real-time qPCR, joints of mice in which CIA had been induced
nd compared them with mice in which CIA had been induced
ut the clinical symptoms were alleviated by pregnancy. We  found
hat arthritic mice had signiﬁcantly higher (almost 50-fold) ratio of
oxp3 mRNA to T cell-marker CD3e mRNA, in their joints, when
ompared to mice protected from arthritic symptoms (Fig. 1C;
 = 0.0028, non-parametric t test). This matches previously reported
ndings in the K/BxN mouse model of rheumatoid arthritis, show-
ng a very high enrichment of Treg in the synovial ﬂuid of arthritic
oints, compared to lymph nodes from the same animals (Nguyen
t al., 2007). In our experiments, non-arthritic non-pregnant con-
rols had no Foxp3 mRNA signal in their joints, as expected by the
ack of any inﬂammation (data not shown).
iscussion
In all models examined, during peak inﬂammation, our ﬁndings
re compatible with an enrichment of Treg either at the site of dis-
ase or its most proximal draining lymph nodes. In atherosclerosis
nd arthritis these may  be tertiary lymphoid structures existing
ithin the affected tissue itself, adjacent to the atherosclerotic
laque (Weih et al., 2012) or in the arthritic synovium (Humby et al.,
009). An important caveat for the interpretation of our arthri-
is and atherosclerosis data is that Foxp3 has been shown to be
xpressed in epithelial cells of breast, lung, prostate and intesti-
al tissue (Chen et al., 2008). Thus we cannot exclude an epithelial
ource of the Foxp3 signal detected in our assays. However, a large
umber of studies have demonstrated that once RA is fully estab-
ished, an enrichment of Treg can be seen in the synovium of human
atients, compared to the levels found in peripheral blood (van
melsfort et al., 2004; Mottonen et al., 2005; Benito-Miguel et al.,
009). This enrichment without resultant immunosuppression
ould appear to contradict the well-characterized Treg poten-
ial to suppress immune responses. Yet the evidence from the
A studies suggests that this enrichment is an insufﬁcient effort
f the immune system to limit the ongoing response. The Treg0.0028, Mann–Whitney test. Values shown are normalized to the mean of animals
 two  independent CIA induction preparations.
appear to be impaired in their ability to suppress (Notley and
Ehrenstein, 2010; Ruprecht et al., 2005) or the pro-inﬂammatory
Teff appear to become refractive to suppression (Benito-Miguel
et al., 2009). This impediment has been attributed to the pro-
duction of pro-inﬂammatory cytokines such as IL-15, IL-7 or IL-6
(Notley and Ehrenstein, 2010; Benito-Miguel et al., 2009; Ruprecht
et al., 2005) by the inﬂamed synovium. Additionally, TNF  ˛ has been
shown to lead to FOXP3 dephosphorylation and consequent inhi-
bition of Treg suppressive activity in rheumatoid arthritis patients
(Nie et al., 2013). Further, soluble cytokine glucocorticoid-induced
TNFR-related protein (sGITR-L) has been shown to abrogate the
ability of Treg to suppress in vitro (Ji et al., 2004). Collectively, these
studies offer clear explanations for the mechanism through which
the pro-inﬂammatory milieu at the site of autoimmune inﬂamma-
tion is paradoxically characterized by lack of suppression despite
an accumulation of Treg.
In animal models of RA, therapeutic interventions that lead to
a reduction of symptoms are associated with a further enrich-
ment of Treg in the arthritic joint (Morgan et al., 2005; Ko et al.,
2010). This lends further support to the notion that the physiolog-
ical enrichment of immunosuppressive Treg at peak inﬂammation
may  represent an unsuccessful or insufﬁcient effort of the immune
system to block or limit the ongoing autoimmune response. Indeed,
an elegant study in the K/BxN model of RA has shown that Treg
are enriched in the synovium of arthritic mice, more so than in
secondary lymph nodes; albeit their immunosuppressive effect
appears to be overwhelmed by the ongoing inﬂammation (Nguyen
et al., 2007).
A number of studies have examined the relative levels of Treg
cells in PBC patients. Yet again, an increase in the number of Treg
cells in the affected tissue, in this case the portal ducts of the liver,
can be observed in PBC patients compared to healthy controls (Lan
et al., 2006; Sasaki et al., 2007; Sakaki et al., 2008; Wang et al.,
2010). Our novel results in the mouse model of PBC are consistent
with these ﬁndings on the Treg enrichment in PBC patients.
Studies in animal models of atherosclerosis have shown
that Treg cells exert suppression on the pro-atherosclerotic,
pro-inﬂammatory Teff responses (Ait-Oufella et al., 2006). Ther-
apeutic interventions in models of the disease were associated
with expanded Treg numbers in the aorta but not the lung mucosa
(Klingenberg et al., 2010). The data we  present here is in agree-
ment with two  recent studies in the aortas of LDL receptor
deﬁcient mouse model of atherosclerosis and in unstable carotid
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laques of human patients, which both identiﬁed a Treg enrichment
Maganto-Garcia et al., 2011; Patel et al., 2010).
A relative enrichment of Treg at the site of inﬂammation, at peak
f disease, has also been reported in experimental autoimmune
ncephalomyelitis (EAE), a model of Multiple Sclerosis (MS). As in
ther diseases, the Treg enrichment was insufﬁcient to control the
isease. This was attributed to production of the cytokines IL-6 and
NF at the site of inﬂammation (Korn et al., 2007); similar ﬁndings
ave also been reported for sarcoidosis (Torgerson, 2006).
Our data, as well the ﬁndings reviewed above, suggest a gen-
ral pattern in the dynamics of Treg cells during the peak phase of
utoimmune inﬂammation: a counter-intuitive, localized enrich-
ent of Treg occurring at the site of inﬂammation. Treg have the
otential to protect from autoimmunity, but once a response has
ommenced, their natural enrichment at the draining lymphoid
tructure closest to the target organ is likely to be an insufﬁcient
ttempt of the immune system to control the inﬂammation. Con-
ersely, healthy or cured tissue is not enriched in Treg cells.
Yet, somewhat surprisingly, the corollary that Treg levels per se
ake a poor indicator of a state of immunosuppression is rarely
ighlighted. As a consequence, Treg abundance in patient periph-
ral blood is increasingly used in clinical and pre-clinical studies
s a marker assumed to be proportional to successful suppression
Lan et al., 2006; Koﬂer et al., 2011). Our ﬁndings suggest that the
bundance of Treg cells per se may  not necessarily be an indication
f whether the response is being successfully suppressed, as abun-
ance of Treg in draining lymphoid structures may  be reﬂective of
ore, not less severe autoimmune inﬂammation. Hence peripheral
lood Treg measurement is of limited diagnostic value, and it may
otentially become a source of misinterpretation.
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